Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Chiome Bioscience Inc. ( (JP:4583) ) is now available.
Chiome Bioscience Inc. announced the publication of results from the first part of its CBA-1205 Phase I clinical study in the journal Cancer Science. The study, involving 22 patients with solid tumors, demonstrated high safety and potential efficacy, with a notable case of a melanoma patient experiencing stable disease for over three years. The results highlight CBA-1205’s promise, especially in melanoma, and indicate DLK1 levels as a potential biomarker for its efficacy, prompting further study and patient enrollment in the next phase of trials.
More about Chiome Bioscience Inc.
Chiome Bioscience Inc. operates in the biotechnology industry, focusing on developing innovative monoclonal antibody therapies. The company is particularly engaged in advancing treatments for cancer, with its proprietary technology Glymax® enhancing antibody activity.
YTD Price Performance: -13.75%
Average Trading Volume: 12,030,205
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen15.54B
Find detailed analytics on 4583 stock on TipRanks’ Stock Analysis page.
